NCT02884635 - A Study to Evaluate the Efficacy and Safety of ASP1707 in Postmenopausal Female Patients With Rheumatoid Arthritis Taking Methotrexate | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 16, 2016

Primary Completion Date

October 18, 2017

Study Completion Date

October 25, 2017

Conditions

Rheumatoid Arthritis

Interventions

DRUG

ASP1707

Oral

DRUG

Placebo

Oral

DRUG

Methotrexate

Methotrexate will be orally administered at stable dose from at least 28 days prior to screening through the screening and treatment periods until the end of the follow-up period.

Trial Locations (27)

Unknown

Site JP00004, Numakunai

Site JP00005, Numakunai

Site JP00022, Aichi

Site JP00023, Aichi

Site JP00017, Chiba

Site JP00026, Ehime

Site JP00025, Fukui

Site JP00012, Fukuoka

Site JP00018, Fukuoka

Site JP00019, Fukuoka

Site JP00006, Gunma

Site JP00024, Gunma

Site JP00010, Hiroshima

Site JP00011, Hiroshima

Site JP00001, Hokkaido

Site JP00002, Hokkaido

Site JP00003, Hokkaido

Site JP00016, Kagoshima

Site JP00007, Kanagawa

Site JP00021, Kanagawa

Site JP00014, Kumamoto

Site JP00015, Kumamoto

Site JP00013, Nagasaki

Site JP00020, Ōita

Site JP00008, Shizuoka

Site JP00009, Shizuoka

Site JP00027, Tokyo